Compare STRIDES PHARMA SCIENCE with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs LUPIN - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE LUPIN STRIDES PHARMA SCIENCE/
LUPIN
 
P/E (TTM) x 42.1 46.3 90.9% View Chart
P/BV x 2.0 4.3 46.1% View Chart
Dividend Yield % 0.2 0.5 48.6%  

Financials

 STRIDES PHARMA SCIENCE   LUPIN
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
LUPIN
Mar-20
STRIDES PHARMA SCIENCE/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,147882 130.0%   
Low Rs642505 127.1%   
Sales per share (Unadj.) Rs317.2339.4 93.5%  
Earnings per share (Unadj.) Rs7.8-5.9 -131.9%  
Cash flow per share (Unadj.) Rs25.115.5 162.0%  
Dividends per share (Unadj.) Rs2.006.00 33.3%  
Dividend yield (eoy) %0.20.9 25.8%  
Book value per share (Unadj.) Rs274.3276.7 99.1%  
Shares outstanding (eoy) m89.50453.00 19.8%   
Bonus / Rights / Conversions ESOPESOP-  
Price / Sales ratio x2.82.0 138.0%   
Avg P/E ratio x114.0-116.6 -97.8%  
P/CF ratio (eoy) x35.744.8 79.6%  
Price / Book Value ratio x3.32.5 130.1%  
Dividend payout %25.5-100.9 -25.3%   
Avg Mkt Cap Rs m80,058314,201 25.5%   
No. of employees `0002.518.3 13.7%   
Total wages/salary Rs m4,34129,868 14.5%   
Avg. sales/employee Rs Th11,325.88,400.6 134.8%   
Avg. wages/employee Rs Th1,731.41,632.0 106.1%   
Avg. net profit/employee Rs Th280.1-147.2 -190.3%   
INCOME DATA
Net Sales Rs m28,394153,748 18.5%  
Other income Rs m9414,838 19.4%   
Total revenues Rs m29,334158,585 18.5%   
Gross profit Rs m3,96524,849 16.0%  
Depreciation Rs m1,5409,702 15.9%   
Interest Rs m1,9623,630 54.1%   
Profit before tax Rs m1,40316,355 8.6%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m-16839 -426.4%   
Extraordinary Inc (Exp) Rs m-436-7,521 5.8%   
Tax Rs m9711,571 0.8%   
Profit after tax Rs m702-2,694 -26.1%  
Gross profit margin %14.016.2 86.4%  
Effective tax rate %6.970.8 9.8%   
Net profit margin %2.5-1.8 -141.1%  
BALANCE SHEET DATA
Current assets Rs m24,836154,132 16.1%   
Current liabilities Rs m18,99392,252 20.6%   
Net working cap to sales %20.640.2 51.1%  
Current ratio x1.31.7 78.3%  
Inventory Days Days7182 86.5%  
Debtors Days Days113129 87.7%  
Net fixed assets Rs m34,28989,082 38.5%   
Share capital Rs m895906 98.8%   
"Free" reserves Rs m23,651124,461 19.0%   
Net worth Rs m24,546125,367 19.6%   
Long term debt Rs m15,51317,933 86.5%   
Total assets Rs m65,437249,839 26.2%  
Interest coverage x1.75.5 31.2%   
Debt to equity ratio x0.60.1 441.8%  
Sales to assets ratio x0.40.6 70.5%   
Return on assets %4.10.4 1,087.0%  
Return on equity %2.9-2.1 -133.1%  
Return on capital %6.98.7 79.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69751,450 30.5%   
Fx outflow Rs m73519,470 3.8%   
Net fx Rs m14,96231,980 46.8%   
CASH FLOW
From Operations Rs m1,87114,688 12.7%  
From Investments Rs m5,82611,070 52.6%  
From Financial Activity Rs m-10,157-8,906 114.0%  
Net Cashflow Rs m-2,61516,853 -15.5%  

Share Holding

Indian Promoters % 27.7 46.6 59.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 37.8 11.3 334.5%  
FIIs % 8.6 31.9 27.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.1 256.4%  
Shareholders   56,241 98,259 57.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   JUBILANT PHARMOVA   DR. DATSONS LABS  WOCKHARDT  NOVARTIS  PANACEA BIOTECH  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 14, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS